BR112022000036A2 - Compostos de 7,8-di-hidro-4h-pirazolo [4,3-c]azepina-6-ona - Google Patents
Compostos de 7,8-di-hidro-4h-pirazolo [4,3-c]azepina-6-onaInfo
- Publication number
- BR112022000036A2 BR112022000036A2 BR112022000036A BR112022000036A BR112022000036A2 BR 112022000036 A2 BR112022000036 A2 BR 112022000036A2 BR 112022000036 A BR112022000036 A BR 112022000036A BR 112022000036 A BR112022000036 A BR 112022000036A BR 112022000036 A2 BR112022000036 A2 BR 112022000036A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- azepine
- pyrazolo
- dihydro
- ch2ch3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
compostos de 7,8-di-hidro-4h-pirazolo [4,3-c]azepina-6-ona. a presente invenção refere-se aos compostos de fórmula i: em que r1 é ch3 ou ch2ch3; e os sais farmaceuticamente aceitáveis do mesmos, os quais são úteis para o tratamento do câncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19382680 | 2019-08-05 | ||
PCT/US2020/044718 WO2021026059A1 (en) | 2019-08-05 | 2020-08-03 | 7,8-DIHYDRO-4H-PYRAZOLO[4,3-c]AZEPINE-6-ONE COMPOUNDS |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022000036A2 true BR112022000036A2 (pt) | 2022-04-26 |
Family
ID=67551324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022000036A BR112022000036A2 (pt) | 2019-08-05 | 2020-08-03 | Compostos de 7,8-di-hidro-4h-pirazolo [4,3-c]azepina-6-ona |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220251096A1 (pt) |
EP (1) | EP4010343B1 (pt) |
JP (1) | JP7293493B2 (pt) |
KR (1) | KR20220029735A (pt) |
CN (1) | CN114269750A (pt) |
AR (1) | AR119557A1 (pt) |
AU (1) | AU2020324949B2 (pt) |
BR (1) | BR112022000036A2 (pt) |
CA (1) | CA3145651A1 (pt) |
ES (1) | ES2963582T3 (pt) |
IL (1) | IL289141A (pt) |
MX (1) | MX2022001412A (pt) |
TW (1) | TW202120095A (pt) |
WO (1) | WO2021026059A1 (pt) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6820254B2 (ja) | 2014-10-10 | 2021-01-27 | ジェネンテック, インコーポレイテッド | 治療用化合物およびその使用 |
JP6771464B2 (ja) | 2014-11-27 | 2020-10-21 | ジェネンテック, インコーポレイテッド | Cbpおよび/またはep300インヒビターとしての、4,5,6,7−テトラヒドロ−1h−ピラゾロ[4,3−c]ピリジン−3−アミン化合物 |
CN115028617A (zh) | 2016-05-24 | 2022-09-09 | 基因泰克公司 | Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途 |
CN109476663B (zh) | 2016-05-24 | 2021-11-09 | 基因泰克公司 | 用于治疗癌症的吡唑并吡啶衍生物 |
JP2019524872A (ja) * | 2016-06-20 | 2019-09-05 | ノバルティス アーゲー | 癌の治療に有用なイミダゾピリミジン化合物 |
-
2020
- 2020-07-30 TW TW109125724A patent/TW202120095A/zh unknown
- 2020-07-31 AR ARP200102171A patent/AR119557A1/es unknown
- 2020-08-03 ES ES20757193T patent/ES2963582T3/es active Active
- 2020-08-03 CA CA3145651A patent/CA3145651A1/en active Pending
- 2020-08-03 CN CN202080058609.8A patent/CN114269750A/zh active Pending
- 2020-08-03 JP JP2022507313A patent/JP7293493B2/ja active Active
- 2020-08-03 KR KR1020227003804A patent/KR20220029735A/ko not_active Application Discontinuation
- 2020-08-03 MX MX2022001412A patent/MX2022001412A/es unknown
- 2020-08-03 BR BR112022000036A patent/BR112022000036A2/pt unknown
- 2020-08-03 US US17/628,659 patent/US20220251096A1/en active Pending
- 2020-08-03 AU AU2020324949A patent/AU2020324949B2/en active Active
- 2020-08-03 WO PCT/US2020/044718 patent/WO2021026059A1/en active Application Filing
- 2020-08-03 EP EP20757193.6A patent/EP4010343B1/en active Active
-
2021
- 2021-12-19 IL IL289141A patent/IL289141A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP7293493B2 (ja) | 2023-06-19 |
EP4010343A1 (en) | 2022-06-15 |
US20220251096A1 (en) | 2022-08-11 |
WO2021026059A1 (en) | 2021-02-11 |
AU2020324949A1 (en) | 2022-01-20 |
AR119557A1 (es) | 2021-12-29 |
KR20220029735A (ko) | 2022-03-08 |
JP2022543277A (ja) | 2022-10-11 |
ES2963582T3 (es) | 2024-04-01 |
AU2020324949B2 (en) | 2023-11-02 |
IL289141A (en) | 2022-02-01 |
TW202120095A (zh) | 2021-06-01 |
CN114269750A (zh) | 2022-04-01 |
CA3145651A1 (en) | 2021-02-11 |
EP4010343B1 (en) | 2023-09-13 |
MX2022001412A (es) | 2022-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019001666A2 (pt) | n-(fenilsulfonil)benzamidas e compostos relacionados como inibidores de bcl-2 | |
BR112015016793A2 (pt) | compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim | |
BR112018070859A2 (pt) | degradantes da proteína de bet | |
BR112016015983A2 (pt) | Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica | |
BR112019007144A2 (pt) | compostos de pirazolo[1,5-a]piridina substituídos como inibidores da ret cinase | |
CY1121357T1 (el) | Νεος ανοσοτροποποιητης και αντιφλεγμονωδεις ενωσεις | |
BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
EA201990833A1 (ru) | Соединение пиридина | |
BR112014001801A2 (pt) | indazóis | |
GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
BR112014013661A8 (pt) | derivados de nucleosídeos 2,4-difluoro-2-metil substituídos como inibidores de replicação de hcv-rna | |
EA201792116A1 (ru) | Ингибитор янус-киназы | |
EA201691428A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
BR112016015449A8 (pt) | compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos | |
BR112013010310A2 (pt) | inibidores de acetil-coa carboxilase de lactama n1/n2 | |
BR112014008495A2 (pt) | inibidores de proteína quinase | |
BR112015025413A2 (pt) | inibidores de proteína cinase | |
MX2015012822A (es) | 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante. | |
BR112018007811A2 (pt) | compostos de imidazo[4,5-c]quinolin-2-ona e seu uso no tratamento do câncer | |
BR112013031402A2 (pt) | derivados de hidantoína como inibidores de kv3 | |
BR112020016020A8 (pt) | Inibidor de atr e aplicação do mesmo | |
BR112022000713A2 (pt) | Imidazopirimidinas como inibidores de eed e o uso das mesmas | |
BR112017027411A2 (pt) | inibidores de nadph oxidase 4 | |
BR112018069712A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a. | |
BR112019003710A2 (pt) | inibidor de pde7, composto, composição farmacêutica, uso de um inibidor de pde7 ou de um composto, e, método para tratar ou prevenir uma doença que é melhorada pela inibição de pde7. |